AgingResearch.NewsJoin free

Phase 1Terminated

A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma

A Dose Escalation and Dose Expansion Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma - CEP-2

Sponsor
Noxopharm Limited (Industry)
Enrollment
9 enrolled
Conditions
Metastatic Soft-tissue Sarcoma
Interventions
NOX66; NOX66; NOX66; NOX66; Doxorubicin
Ages
adults, older adults
Registry
NCT05100628

Full record on ClinicalTrials.gov

From the registry

This is a Phase I, open-label, dose-escalation and dose-expansion study of NOX66 given rectally, in cohorts of patients with metastatic soft tissue sarcoma (STS) who have not been exposed to anthracycline therapy, using a fixed dose-escalation schema every 21 days to establish the maximum tolerated dose (MTD) of the combination of NOX66 and doxorubicin.

Primary outcomes

  • Dose Escalation: Number of Patients With Dose-limiting Toxicities (DLTs)
  • Number of Patients With Adverse Events (AEs) for NOX66

History

  1. Results first posted

  2. Last registry update

  3. Study completion

  4. Primary completion

  5. Started

  6. Registered